Merck KGaA & MorphoSys Sign Deal, Immuno-Oncology in Focus - Analyst Blog

By
A A A

Merck KGaA ( MKGAF ) and MorphoSys AG announced that they have inked a deal to discover and develop therapeutic antibodies against undisclosed immune checkpoints. MorphoSys will work with Merck KGaA's biopharmaceutical division, Merck Serono, to develop therapies that modulate the natural capability of the immune system to fight tumors.

Terms of the Deal

According to the agreement, MorphoSys' proprietary Ylanthia antibody phage library and technology platform will help in the identification of the targeted antibodies. Meanwhile, Merck Serono's expertise in the field of immuno-oncology will come in handy for development from phase I onwards. Merck Serono will be solely responsible for commercializing any products resulting from this agreement.


As per the deal, the cost of research & development will be shared by MorphoSys and Merck KGaA. However, MorphoSys holds the right to-opt out at predefined stages. MorphoSys will receive milestone payments on the achievement of certain development and commercial goals. Additionally, it will receive tiered royalties on sales of products depending on the extent of its co-funding.

Our Take

With this deal, Merck KGaA's cancer immunotherapy portfolio, which consists of both early-stage and late-stage candidates, will be strengthened further.

Of late, immuno-oncology has attracted the interest of several companies. Many companies have immuno-oncology candidates in their pipeline and are tying up with other companies as well. Last month, AstraZeneca plc ( AZN ) tied up with Incyte Corporation ( INCY ) for the development of its investigational immunotherapy, MEDI4736, in combination with Incyte's INCB24360 for the treatment of cancer.

Merck KGaA carries a Zacks Rank #3 (Hold). A better-ranked stock in the health care sector is ANIP Pharmaceuticals Inc. ( ANIP ) carrying a Zacks Rank #1 (Strong Buy).


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ASTRAZENECA PLC (AZN): Free Stock Analysis Report

MERCK KGAA (MKGAF): Get Free Report

INCYTE CORP (INCY): Free Stock Analysis Report

ANI PHARMACEUT (ANIP): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.




This article appears in: Investing , Business , Stocks

Referenced Stocks: AZN , MKGAF , INCY , ANIP

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

64,655,493
  • $17.88 ▼ 1.38%
53,363,101
  • $18.51 ▼ 6.98%
42,787,995
  • $94.01 ▼ 1.26%
40,818,762
  • $121.30 ▼ 0.87%
38,086,152
  • $23.28 ▼ 9.17%
36,103,930
  • $14.20 ▼ 0.77%
31,870,696
  • $14.83 ▼ 1.79%
29,019,850
  • $46.70 ▼ 0.38%
As of 7/31/2015, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com